# A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

> **NCT00144768** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 25 (estimated)

## Conditions studied

- Mucopolysaccharidosis I
- Hurler's Syndrome
- Hurler-Scheie Syndrome
- Scheie's Syndrome

## Interventions

- **DRUG:** laronidase

## Key facts

- **NCT ID:** NCT00144768
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2014-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144768, "A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00144768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*